$PROK News
Last published 2d ago
- 2d agoPROKGuggenheim 3rd Annual Healthcare Innovation Conference - PROKIDNEY CORPEarnings Call TranscriptsThanks, everyone, for joining us again this year for the Guggenheim Healthcare Innovation Conference. I'm Bob LeVon, one of the biopharm analysts here at Guggeheim. And joining us next in this room, we have the ProKidney
- 2d agoPROKGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - PROKIDNEY CORPEarnings Call TranscriptsThanks, everyone, for joining us again this year for the Guggenheim Healthcare Innovation Conference. I'm Bob LeVon, one of the biopharm analysts here at Guggeheim. And joining us next in this room, we have the ProKidney
- 2d agoPROKPROKIDNEY CORP. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 8.01 Item 9.01
- 2w agoPROKProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate UpdateGlobeNewswireWINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease
- 2w agoPROKProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026GlobeNewswireSeven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencelOne clinical abstract presents a new
- 3mo agoPROKProKidney Reports Second Quarter 2026 Financial Results and Business HighlightsGlobeNewswireCompleted enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027On track for completion
- 5mo agoPROKProKidney Appoints Kenneth Locke as Chief Technical OfficerGlobeNewswireWINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today
- 6mo agoPROKProKidney Reports First Quarter 2026 Financial Results and Business HighlightsGlobeNewswireOn track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027Peer-reviewed results from the Phase 2 REGEN-007 study were
- 7mo agoPROKProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial OfficerGlobeNewswireWINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD),
- 8mo agoMLYSPROKIRONREGN+5Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsightPR NewswireRecently published Chronic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, chronic...
- 11mo agoPROKMESOLCTXBeyond Insulin Pumps: Cell Therapies Unlock a $403B Cure EconomyPR NewswireThe cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations...
- 1y agoPROKProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical UpdatesGlobeNewswireFull results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the patients required
- 1y agoPROKProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025GlobeNewswireIn patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral kidney injection with
- 1y agoPROKProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare ConferenceGlobeNewswireWINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease
- 1y agoPROKProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025GlobeNewswireWINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease
- 1y agoPROKProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoPROKProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoPROKProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare ConferenceGlobeNewswireWINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease
- 1y agoPROKProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical UpdatesGlobeNewswireFDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type 2 diabetes and advanced
- 1y agoPROKProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for RilparencelGlobeNewswireFDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for
- 1y agoPROKProKidney Corp. Completes Domestication from the Cayman Islands to DelawareGlobeNewswireWINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease
- 1y agoPROKProKidney Reports First Quarter 2025 Financial Results and Business HighlightsGlobeNewswireFull data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on the
- 1y agoPROKProKidney Reports Full Year 2024 Financial Results and Business HighlightsGlobeNewswireSignificant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, and securing $140
- 1y agoPROKKuehn Law Encourages Investors of ProKidney Corp. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ProKidney Corp. (NASDAQ: PROK)...
- 1y agoPROKProKidney to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for
- 1y agoPROKProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare ConferenceGlobeNewswireWINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for
- 1y agoPROKProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B MeetingGlobeNewswireFDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencelFDA also confirmed in that Type B meeting
- 2y agoPROKProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare ConferenceGlobeNewswireWINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for
- 2y agoPROKProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024GlobeNewswireWINSTON-SALEM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease
- 2y agoPROKProKidney to Participate in the UBS Virtual Organ Restoration DayGlobeNewswireWINSTON-SALEM, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for
- 2y agoPROKProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.GlobeNewswireRefined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company's highest priority marketDiscontinued the ex-U.S.-based PROACT 2 trial and focused Company
- 2y agoPROKProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewswireWINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate
- 2y agoPROKProKidney Reports Business Updates and Second Quarter 2024 Financial ResultsGlobeNewswireReported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and advanced CKDRestarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3
- 2y agoPROKProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters' OptionGlobeNewswireWINSTON-SALEM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today
- 2y agoPROKProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct OfferingGlobeNewswireWINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today
- 2y agoPROKProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct OfferingGlobeNewswireWINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease,
- 2y agoPROKProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational UpdatesGlobeNewswireInterim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and both PROACT 1 and PROACT
- 2y agoPROKProKidney to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireWINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced
- 2y agoPROKProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024GlobeNewswireWINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease
- 2y agoPROKProKidney Reports Business Updates and First Quarter 2024 Financial ResultsGlobeNewswireFinal results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD
- 2y agoALCEBYNCLINPNST+4Wolf Popper LLP Announces Investigations on Behalf of Investors in Materially Underperforming Special Purpose Acquisition CompaniesGlobeNewswireNEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of investors in the following Special Purpose Acquisition Companies (SPAC). The stock prices of these companies,
- 2y agoPROKProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical OperationsGlobeNewswireDr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies Mr. Lucio Tozzi joined in January of 2024 as
- 2y agoPROKProKidney Reports Full Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireWINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease
- 2y agoPROKProKidney to Participate in Jefferies Biotech on the Bay SummitGlobeNewswireWINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced
- 2y agoPROKProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business OfficerGlobeNewswireWINSTON-SALEM, N.C., Nov. 30, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced
- 2y agoPROKProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx ConferenceGlobeNewswireWINSTON-SALEM, N.C, Nov. 21, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in
- 2y agoPROKProKidney Corp. (PROK) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoPROKProKidney Reports Third Quarter Financial ResultsGlobeNewswireWINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced
- 2y agoPROKProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate UpdatesGlobeNewswireUpdated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients Focusing Phase 3 development program on patients with Stage
- 3y agoPROKProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023GlobeNewswireWINSTON-SALEM, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced